Bromocriptine

In the clinical diagnosis and treatment of prolactin-related diseases, dopamine receptor agonists are the core drug category, and bromocriptine is a classic representative in this field. As a semi-synthetic ergot alkaloid derivative, it can selectively activate dopamine D2 receptors in the hypothalamus and pituitary gland, directly inhibit the synthesis and secretion of prolactin, and partially inhibit the release of growth hormone. In clinical practice, it is not only used for the long-term control of hyperprolactinemia and prolactinoma to improve symptoms such as amenorrhea, galactorrhea and reproductive dysfunction, but also can be used as an adjuvant treatment for Parkinson's disease and acromegaly, and can also be used for postpartum lactation regression. The applicable population covers patients in multiple departments such as endocrinology, neurology, obstetrics and gynecology.

The current global market size of bromocriptine API is approximately USD 120 million, with a compound annual growth rate of around 3.7% in the past three years. The demand growth mainly comes from the improved diagnosis rate of prolactinoma in emerging markets and the increase in the patient base of Parkinson's disease. In terms of the competitive landscape, the API production capacity of the original manufacturer is prioritized to supply its own preparation production, and the supply of generic API is mainly concentrated in Chinese and Indian manufacturers. Among them, Chinese manufacturers account for 42% of the global generic API supply, and their impurity control levels generally meet the regulatory requirements of mainstream markets, making them the main procurement source for global generic drug companies.

CATO can provide a full set of impurity reference standards for bromocriptine API. All products are available in stock and meet the quality standards of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. They can directly support the quality research, stability study and registration declaration of API, helping manufacturers shorten the R&D cycle and reduce compliance risks.